Edition:
United States

Sienna Biopharmaceuticals Inc (SNNA.OQ)

SNNA.OQ on NASDAQ Stock Exchange Global Select Market

9.66USD
3:06pm EST
Change (% chg)

$-0.29 (-2.91%)
Prev Close
$9.95
Open
$9.78
Day's High
$10.95
Day's Low
$9.49
Volume
6,118
Avg. Vol
17,342
52-wk High
$25.58
52-wk Low
$9.01

Latest Key Developments (Source: Significant Developments)

Sienna Biopharmaceuticals Reports Qtrly Loss Per Share $0.85
Monday, 14 May 2018 09:05am EDT 

May 14 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.SIENNA BIOPHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.85.  Full Article

Sienna Biopharmaceuticals Appoints John Smither As CFO
Wednesday, 21 Mar 2018 05:30pm EDT 

March 21 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS APPOINTS JOHN W. SMITHER AS CHIEF FINANCIAL OFFICER.SIENNA BIOPHARMACEUTICALS INC - ‍SMITHER WILL SUCCEED RICHARD PETERSON, WHO HAS RESIGNED FOR PERSONAL REASONS, EFFECTIVE MAR. 29, 2018​.  Full Article

Sienna Biopharmaceuticals Qtrly Loss Per Share $0.56
Thursday, 15 Mar 2018 09:05am EDT 

March 15 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.SIENNA BIOPHARMACEUTICALS INC - CASH AND CASH EQUIVALENTS AS OF DEC 31, 2017 TOTALED APPROXIMATELY $74.5 MILLION.SIENNA BIOPHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.56.  Full Article

Sienna Biopharma Announces First Patient Dosed In First-In-Human Trial Of Topical SNA-125
Wednesday, 14 Feb 2018 09:05am EST 

Feb 14 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN FIRST-IN-HUMAN TRIAL OF TOPICAL SNA-125.SIENNA BIOPHARMACEUTICALS INC - TOP-LINE RESULTS FROM STUDY EXPECTED IN Q3 OF 2018.SIENNA BIOPHARMACEUTICALS INC - PLAN TO INITIATE SNA-125 PROOF-OF-CONCEPT TRIAL FOR ATOPIC DERMATITIS AND EXPECT THOSE DATA IN SECOND HALF OF 2018.SIENNA BIOPHARMACEUTICALS- EXPECT TO REPORT TOP-LINE DATA IN 1H 2019 FROM SNA-120 PHASE 2B CLINICAL TRIAL FOR PRURITUS & ASSOCIATED UNDERLYING PSORIASIS.  Full Article

Sienna Biopharmaceuticals posts qtrly loss per share $1.12‍​
Thursday, 9 Nov 2017 08:05am EST 

Nov 9 (Reuters) - Sienna Biopharmaceuticals Inc :Sienna Biopharmaceuticals reports third quarter 2017 financial results.Sienna Biopharmaceuticals Inc - Qtrly loss per share $1.12‍​.Sienna Biopharmaceuticals Inc - ‍Sienna's cash and cash equivalents as of Sept. 30, 2017, totaled approximately $88.6 million​.Sienna Biopharmaceuticals - ‍ Expects non-cash component related to acquisition of creabilis to continue to impact G&A expenses in future quarters​.  Full Article

Sienna Biopharmaceuticals announces first patient dosed in phase 2B trial of topical SNA-120
Tuesday, 24 Oct 2017 09:05am EDT 

Oct 24 (Reuters) - Sienna Biopharmaceuticals Inc :Sienna Biopharmaceuticals announces first patient dosed in phase 2B trial of topical SNA-120.Sienna Biopharmaceuticals Inc - ‍top-line results expected in first half of 2019​.Sienna Biopharmaceuticals - ‍phase 2B trial of topical SNA-120 to enroll about 190 patients with Pruritus associated with psoriasis​.  Full Article

Sienna Biopharmaceuticals reports Q2 loss of $6.50/shr
Thursday, 7 Sep 2017 08:05am EDT 

Sept 7 (Reuters) - Sienna Biopharmaceuticals Inc :Sienna Biopharmaceuticals reports second quarter 2017 financial results.Qtrly loss per share $6.50.  Full Article

Partner Fund reports 7.7 pct passive stake in Sienna Biopharmaceuticals‍​
Monday, 7 Aug 2017 04:50pm EDT 

Aug 7 (Reuters) - Sienna Biopharmaceuticals Inc :Partner Fund Management LP reports 7.7 percent passive stake in Sienna Biopharmaceuticals Inc as of July 27, 2017 - SEC filing‍​.  Full Article

Sienna Biopharmaceuticals shares open 27 pct above IPO price in debut
Thursday, 27 Jul 2017 10:26am EDT 

July 27 (Reuters) - :Sienna Biopharmaceuticals Inc shares open at $19.05 in debut on the NASDAQ versus IPO price of $15.00.  Full Article

Sienna Biopharmaceuticals expects IPO price between $14.00-$16.00 per share‍​
Monday, 17 Jul 2017 08:34am EDT 

July 17 (Reuters) - Sienna Biopharmaceuticals Inc :Sienna Biopharmaceuticals Inc - sees ipo of 4.3 million shares - SEC filing‍​.Sienna Biopharmaceuticals Inc - expect that the initial public offering price will be between $14.00 and $16.00 per share‍​.  Full Article

Sienna Biopharma sinks after acne treatment fails two trials

Sienna Biopharmaceuticals Inc said its lead experimental acne treatment failed to meet the main goals of two pivotal trials and that the chances of it clearing a third study appeared weaker, sending its shares tumbling 19 percent.